Clinical Trial Update: A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated adding tocilizumab to non-biologic DMARDs in adults with moderate-to-severe rheumatoid arthritis who had an inadequate response to non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2015-02-06